NZ586025A - Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate - Google Patents

Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate

Info

Publication number
NZ586025A
NZ586025A NZ586025A NZ58602509A NZ586025A NZ 586025 A NZ586025 A NZ 586025A NZ 586025 A NZ586025 A NZ 586025A NZ 58602509 A NZ58602509 A NZ 58602509A NZ 586025 A NZ586025 A NZ 586025A
Authority
NZ
New Zealand
Prior art keywords
ethyl acrylate
acrylate copolymer
methacrylic acid
tablet
rasagiline mesylate
Prior art date
Application number
NZ586025A
Other languages
English (en)
Inventor
Muhammad Safadi
Dannit Licht
Rachel Cohen
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NZ586025A publication Critical patent/NZ586025A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ586025A 2008-01-11 2009-01-09 Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate NZ586025A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1086008P 2008-01-11 2008-01-11
PCT/US2009/000134 WO2009089049A1 (en) 2008-01-11 2009-01-09 Rasagiline formulations, their preparation and use

Publications (1)

Publication Number Publication Date
NZ586025A true NZ586025A (en) 2012-08-31

Family

ID=40850833

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ586025A NZ586025A (en) 2008-01-11 2009-01-09 Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate

Country Status (15)

Country Link
US (1) US20090181086A1 (https=)
EP (1) EP2234478A4 (https=)
JP (2) JP5583597B2 (https=)
KR (1) KR20100107028A (https=)
CN (1) CN101909438A (https=)
AU (1) AU2009204454B2 (https=)
BR (1) BRPI0905680A2 (https=)
CA (1) CA2711817A1 (https=)
EA (1) EA201070842A1 (https=)
IL (1) IL206136A0 (https=)
MX (1) MX2010007601A (https=)
NZ (1) NZ586025A (https=)
SG (1) SG187455A1 (https=)
WO (1) WO2009089049A1 (https=)
ZA (1) ZA201004086B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CA2646250A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ZA200903903B (en) * 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
MX2010013875A (es) 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010341499A1 (en) 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド R(+)−n−メチル−プロパルギルアミノインダン
WO2013055687A2 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline
AU2023377801A1 (en) * 2022-11-07 2025-06-19 Natural MedTech Pty Ltd Tryptamine formulations and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
ES2107235T3 (es) * 1993-06-14 1997-11-16 Janssen Pharmaceutica Nv Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de) * 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20050220864A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
CA2575006A1 (en) * 2004-07-26 2006-02-02 E. Itzhak Lerner Dosage forms with an enterically coated core tablet
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ZA200903903B (en) * 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
MX2010013875A (es) * 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
EA201170181A1 (ru) * 2008-07-11 2011-08-30 Синтон Бв Полиморфные формы разагилина гидрохлорида
US20100029987A1 (en) * 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282716A1 (en) * 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
CA2806740A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
US20120101168A1 (en) * 2010-10-26 2012-04-26 Eliezer Bahar Deuterium enriched rasagiline
JP2014534197A (ja) * 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド R(+)−n−メチル−プロパルギルアミノインダン
WO2013055687A2 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
CN103857389A (zh) * 2011-10-10 2014-06-11 泰华制药工业有限公司 雷沙吉兰柠檬酰胺

Also Published As

Publication number Publication date
WO2009089049A1 (en) 2009-07-16
BRPI0905680A2 (pt) 2015-07-07
AU2009204454B2 (en) 2015-02-05
AU2009204454A1 (en) 2009-07-16
KR20100107028A (ko) 2010-10-04
SG187455A1 (en) 2013-02-28
IL206136A0 (en) 2010-11-30
CN101909438A (zh) 2010-12-08
ZA201004086B (en) 2011-08-31
EP2234478A4 (en) 2013-01-23
JP2011509295A (ja) 2011-03-24
CA2711817A1 (en) 2009-07-16
JP2014237668A (ja) 2014-12-18
MX2010007601A (es) 2010-08-03
JP5583597B2 (ja) 2014-09-03
US20090181086A1 (en) 2009-07-16
EA201070842A1 (ru) 2011-04-29
EP2234478A1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
NZ586025A (en) Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
JP2011509295A5 (https=)
JP2017128614A5 (https=)
EP4631571A3 (en) Combination of dextromethorphan and bupropion for treating depression
NZ589445A (en) Rasagiline for parkinson's disease modification
AR075148A1 (es) Formulacion de rasagilina de liberacion retardada. proceso para fabricar citrato de rasagilina
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ620879A (en) A novel formulation of indomethacin
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
CA2393437A1 (en) Exo-s-mecamylamine formulation and use in treatment
NZ606825A (en) Methods and compositions for treating complement-associated disorders
NZ598534A (en) Dosage regimen of an s1p receptor modulator
JP2009143964A5 (https=)
NZ610701A (en) Once daily formulation of lacosamide
NZ593467A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
NZ710383A (en) A novel formulation of diclofenac
JP2013531041A5 (https=)
JP2013507352A5 (https=)
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
JP2014534197A5 (https=)
JP2013502446A5 (https=)
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
JP2020513032A5 (https=)
RU2015140572A (ru) Способы лечения колоректального рака
JP2015517994A5 (https=)

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JAN 2016 BY DENNEMEYER SA

Effective date: 20130308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JAN 2019 BY DENNEMEYER + CO

Effective date: 20140828

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 09 JAN 2029 BY DENNEMEYER + CO

Effective date: 20140828

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JAN 2022 BY DENNEMYER + CO

Effective date: 20140828